CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

Pharmacogenomics

Volumn 3, Issue 2, 2002, Pages 229-243

  Bradford, L DiAnne ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Allele frequency; CYP2D6 polymorphism; Genotype; Racial ethnic

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT; OPIATE;

AFRICA; ALLELE; AMERICAN INDIAN; ASIAN; CANADA; CAUCASIAN; CENTRAL AMERICA; DOSE RESPONSE; DRUG METABOLISM; ENZYME METABOLISM; ETHNIC GROUP; EUROPE; GENE ACTIVITY; GENE FREQUENCY; GENE FUNCTION; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MEDICAL INFORMATION; METABOLIC RATE; NEGRO; PACIFIC ISLANDS; PHARMACOGENETICS; POPULATION RESEARCH; REVIEW; SOUTH AMERICA;

AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; ETHNIC GROUPS; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; UNITED STATES;

EID: 0036124107     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.2.229     Document Type: Review

References (62)

1. Nomenclature for human CYP2D6 alleles
2. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
3. Interethnic factors affecting drug response
4. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population
5. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
6. Molecular mechanisms of genetic polymorphisms of drug metabolism
7. Disposition of debrisoquine in Caucasians with different CYP2D6-geneotypes including those with multiple genes
8. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes
9. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanians population causing reduced catalytic activity
10. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6
11. Cytochrome P450 2D6 (CYP2D6) Genotype-Phenotype Discordance and unique activity distribution towards dextromethorphan in an African American population: Identification of 2D6*40, a novel allelic variant
12. Geographical/interracial differences in polymorphic drug oxidation
13. Polymorphism of CYP2D6 in black populations: Implications for psychopharmacology
14. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations
15. Debrisoquine oxidation polymorphism in a Spanish population
16. Assessment of the debrisoquin and dextromethorphan phenotyping tests by guassian mixture distributions analysis
17. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles
18. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California
19. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
20. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
21. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
22. Polymorphism in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: A role for the CYP2D6*35 allele in ultrarapid metabolism?
23. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Columbian population
24. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population
25. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians
26. Genetic analysis of the CYP2D6 locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects
27. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
28. Genetic analysis of the Chinese Cytochrome P4502D6 locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
29. Kobayashi. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population
30. CYP2D6 genotypes in a Japanese population: Low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
31. Heterogeneity of the CYP2D6 gene among Malays in Malyasia
32. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6
33. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin
34. Interethnic variation in drug metabolism
35. Pharmacokinetics and other related factors affecting psychotropic responses in Asians
36. Ethnicity and Psychopharmacology
37. Ethnicity and psychopharmacology: Bridging the gap
38. CYP2D6 phenotype and genotype in a Canadian native indian population
39. CYP2D6-related oxidation polymorphism in a Canadian Inuit population
40. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Amerindians of Panama and Colombia: Role of selection versus drift in world populations
41. Genetic polymorphism of CYP2D6, CYP1A1, and CYP2E1 in the South-Amerindian population of Chile
42. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population
43. CYP2D6 polymorphism in a Gabonese population: Contribution of the 2D6*2 and 2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
44. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population
45. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs
46. Decreased capacity for debrisoquine metabolism among black Tanzanians: Analysis of the CYP2D6 genotype and phenotype
47. Frequent distribution of Ultrarapid Metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
48. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
49. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function
50. Genetic Basis for a Lower Prevalence of Deficient CYP2D6 Oxidative Drug Metabolism Phenotypes in Black Americans
51. High Frequency of Reduced CYP2D6 Enzyme Activity in African Americans
52. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians
53. High Frequency of CYP2D6 poor and 'intermediate' metabolizers in Black Populations: A review and preliminary data
54. Polymorphism of the cytochrome P450 CYP2D5 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
55. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
56. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population
57. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demthylation in different CYP2D6 genotypes
58. CYP2D6 polymorphism in a Mexican American population
59. Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients
60. CYP2D6 carrying-1496G confer faster 2D6 activity in Caucasians and African Americans than 2D6-1496C variants